+44-1518-0811362025: Volume 9, Issue 2
Editorial P.1-2
Psychological Benefits of Sustained Virological Response: A Pathway to Mental Wellness in Chronic Viral Infections
Author(s):
Chou Chen
DOI: 10.35841/AAVRJ-9.2.191
Editorial P.1-2
SVR in Special Populations: Children, Pregnant Women, and Immunocompromised Patients
Author(s):
Nari Kononov
DOI: 10.35841/AAVRJ-9.2.192
Editorial P.1-2
RNA Interference as a Therapeutic Tool Against Viral Infections
Author(s):
Alessandra Tarlinto
DOI: 10.35841/AAVRJ-9.2.193
Editorial P.1-2
Nanoparticle-Delivered Antivirals: Enhancing Efficacy and Bioavailability
Author(s):
Chao Johnson
DOI: 10.35841/AAVRJ-9.2.194
Editorial P.1-2
Targeting Viral Latency: Strategies for Eradicating Persistent Infection
Author(s):
Edward Carl
DOI: 10.35841/AAVRJ-9.2.195
Editorial P.1-2
The Role of Lipid Metabolism in Antiviral Drug Targeting
Author(s):
Palmer Ikeda
DOI: 10.35841/AAVRJ-9.2.196
Editorial P.1-2
Antivirals for Zoonotic Viruses: Preparing for the Next Spillover
Author(s):
Tamia Anand
DOI: 10.35841/AAVRJ-9.2.197
Editorial P.1-2
Therapeutic Synergy: Combining Antivirals with Immunomodulators
Author(s):
Jerome Pacheco
DOI: 10.35841/AAVRJ-9.2.198
Editorial P.1-2
Is the Antibiotic Pipeline Running Dry?
Author(s):
Kadiyali Srivatsa
DOI: 10.35841/AAVRJ-9.2.199
Editorial P.1-2
The Global Threat of Drug Resistance: Are We Prepared?
Author(s):
Thomas Regan
DOI: 10.35841/AAVRJ-9.2.200